We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
mRNA Booster Vaccine Significantly Increased SARS-CoV-2 Neutralizing Antibodies
News

mRNA Booster Vaccine Significantly Increased SARS-CoV-2 Neutralizing Antibodies

mRNA Booster Vaccine Significantly Increased SARS-CoV-2 Neutralizing Antibodies
News

mRNA Booster Vaccine Significantly Increased SARS-CoV-2 Neutralizing Antibodies

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "mRNA Booster Vaccine Significantly Increased SARS-CoV-2 Neutralizing Antibodies"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

A third dose of the Pfizer-BioNTech vaccine significantly increased neutralizing antibody levels against SARS-CoV-2, the virus that causes COVID-19, according to new research published in the New England Journal of Medicine.

Pfizer, BioNTech and University of Texas Medical Branch scientists tracked the immune response of participants in clinical trials for the vaccine. They found that neutralizing antibody levels, the key protective immunity, dropped significantly over seven to nine months after the two-dose vaccination. This drop of neutralizing antibody levels correlates to the observation of breakthrough infections in vaccinated individuals. After a third dose of the Pfizer-BioNTech vaccine, the neutralizing antibody levels increased many-fold higher than that after the second dose. More importantly, the third dose increased the antibody’s ability to inhibit variants more efficiently, including Beta and Delta variants.

“The safety and antibody response of a booster dose administered seven to nine months after the regular two-dose series suggests that a third dose could prolong protection and further increase the breadth of protection against variants,” said Pei-Yong Shi, professor in the Department of Biochemistry and Molecular Biology at UTMB, who is responsible for the neutralization study detailed in the publication.

Reference:
Falsey AR, Frenck RW, Walsh EE, et al. SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. N Engl J Med. 2021. doi: 10.1056/NEJMc2113468.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement